乳酸左氧氟沙星治疗COPD急性发作48例临床研究

目的：评价乳酸左氧氟沙星治疗ＣＯＰＤ急性发作的临床疗效。方法：在常规治疗的基础上，治疗组４８例用乳酸左氧氟沙星１００～２００ｍ ｇ ｉｖ ｇｔｔｂｉｄ；对照组４７例用氧氟沙星２００ｍ ｇ ｉｖ ｇｔｔｂｉｄ，疗程均为７～１０ｄ。结果：治疗组症状改善有效率为９１．６６％ ，胸片血象好转有效率８９．３６％ ；对照组则分别为５９．５０％ 、５１．０６％ 。两组差异显著（Ｐ＜ ０．０１）。痰培养阳性率分别７２．９２％ 、７０．２１％ ；治疗后细菌清除率分别为９４．２８％ 、７８．７８％ 。不良反应少且轻微。结论：乳酸左氧氟沙星治疗ＣＯＰＤ高效、安全。

Clinical observation of levofloxacin lactate in treatment of 48 patients with chronic obstructive pulmonary disease

Objective: To observe the effects of levofloxacin lactate (LVLXLAC) in treating actue exacerbation of chronic obstructive pulmonary disease (COPD). Methods: The therapeutic group ( n =48) was treated with injection LVLXLAC 100~200mg, iv drip bid for 7~10d with the routine therapy, and the control group ( n =47) received ofloxacin (OFLX) 200mg iv drip bid for the same lenght of time. Results: The total effective rates of the therapy and control groups were 91.66% and 59.50%, the improval rates of chest X ray film and lecuocyte were 89.31% and 51.06% ( P <0.01), the bacterial negative conversion rates were 72.92% and 70.21%, the eliminaation rates were 94.29% and 78.78%, respectively. The adverse reaction of LVLXLAC were mild and less. Conclusion: LVLXLAC is a potent and antibacterial agent for the treatment of COPD.